FR2706772B1 - - Google Patents
Info
- Publication number
- FR2706772B1 FR2706772B1 FR9307559A FR9307559A FR2706772B1 FR 2706772 B1 FR2706772 B1 FR 2706772B1 FR 9307559 A FR9307559 A FR 9307559A FR 9307559 A FR9307559 A FR 9307559A FR 2706772 B1 FR2706772 B1 FR 2706772B1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307559A FR2706772A1 (en) | 1993-06-22 | 1993-06-22 | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307559A FR2706772A1 (en) | 1993-06-22 | 1993-06-22 | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2706772A1 FR2706772A1 (en) | 1994-12-30 |
| FR2706772B1 true FR2706772B1 (US20100056889A1-20100304-C00004.png) | 1995-09-01 |
Family
ID=9448412
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9307559A Granted FR2706772A1 (en) | 1993-06-22 | 1993-06-22 | Prevention and treatment of septic syndrome with an immunosuppressant, in particular cyclosporin. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2706772A1 (US20100056889A1-20100304-C00004.png) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7662776B2 (en) | 2005-07-05 | 2010-02-16 | Biotempt B.V. | Treatment of tumors using short peptides from human chorionic gonadotropin (HCG) |
| US7795226B2 (en) | 2006-03-07 | 2010-09-14 | Biotempt B.V. | Control of radiation injury |
| US7820617B2 (en) | 1998-05-20 | 2010-10-26 | Biotempt B.V. | Methods of selecting immunoregulator peptides obtained from gonadotropins |
| US7928074B2 (en) | 2002-12-30 | 2011-04-19 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| USRE43309E1 (en) | 2000-03-29 | 2012-04-10 | Biotempt B.V. | Immunoregulatory compositions |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| ES2615357T3 (es) | 1996-12-06 | 2017-06-06 | Amgen Inc. | Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1 |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| FI104363B (fi) * | 1997-05-19 | 2000-01-14 | Timo Kalevi Korpela | Immunosuppressanttien ja interferonien farmakologisten keskinäisten vaikutusten parantaminen lisäaineilla |
| US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| US7175679B2 (en) | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
| US6921751B1 (en) | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| US7576174B2 (en) | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| CA2824167C (en) | 2002-09-06 | 2018-09-25 | Amgen Inc. | Therapeutic human anti-il-1r1 monoclonal antibody |
| US7517529B2 (en) | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| US20210236599A1 (en) | 2018-08-13 | 2021-08-05 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2023222565A1 (en) | 2022-05-16 | 2023-11-23 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672496B3 (fr) * | 1990-07-18 | 1993-05-28 | Vacsyn France Sa | Compositions a base de substances hydrophobes, solubilisables dans un solvant aqueux, leur procede d'obtention, et leurs utilisations notamment dans le domaine pharmaceutique. |
| FR2674433A1 (fr) * | 1991-03-27 | 1992-10-02 | Pasteur Institut | Medicament contenant un agent inhibant in vivo l'apoptose pathologique et applications. |
-
1993
- 1993-06-22 FR FR9307559A patent/FR2706772A1/fr active Granted
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820617B2 (en) | 1998-05-20 | 2010-10-26 | Biotempt B.V. | Methods of selecting immunoregulator peptides obtained from gonadotropins |
| USRE43309E1 (en) | 2000-03-29 | 2012-04-10 | Biotempt B.V. | Immunoregulatory compositions |
| US7928074B2 (en) | 2002-12-30 | 2011-04-19 | Amgen Inc. | Combination therapy with co-stimulatory factors |
| US7662776B2 (en) | 2005-07-05 | 2010-02-16 | Biotempt B.V. | Treatment of tumors using short peptides from human chorionic gonadotropin (HCG) |
| US7795226B2 (en) | 2006-03-07 | 2010-09-14 | Biotempt B.V. | Control of radiation injury |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2706772A1 (en) | 1994-12-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse | ||
| ST | Notification of lapse |